Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

The actions of many drugs involve enzyme inhibition. This is exemplified by the inhibitors of
monoamine oxidases (MAO) and the cholinsterases (ChE) that have been used for several …

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition
with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) …

Abstract The cholinesterase inhibitors (ChE-Is) attenuate the cholinergic deficit underlying
the cognitive and neuropsychiatric dysfunctions in patients with AD. Inhibition of brain …

Objective: To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and
neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting …

In Alzheimer disease (AD), which is the most common cause of dementia, the underlying
disease pathology most probably precedes the onset of cognitive symptoms by many years …

Cholinergic degeneration is significant in Lewy body disease, including Parkinson's
disease, dementia with Lewy bodies, and isolated REM sleep behaviour disorder. Extensive …

The deficiency in cholinergic neurotransmission in Alzheimer's disease has led to the
development of cholinesterase inhibitors as the first-line treatment for symptoms of this …

Alzheimer's Disease (AD), the leading cause of senile dementia, is a progressive
neurodegenerative disorder affecting millions of people worldwide and exerting tremendous …

Donepezil is the leading compound for the treatment of Alzheimer's disease (AD) in more
than 50 countries. As compared with other conventional acetylcholinesterase inhibitors …